<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Plus Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/plus-therapeutics-inc</link>
<description>Latest news and press releases for Plus Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/plus-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b1db78dffbe2df11095b.webp</url>
<title>Plus Therapeutics Inc</title>
<link>https://6ix.com/company/plus-therapeutics-inc</link>
</image>
<item>
<title>Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
<description>HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that, for the 10</description>
</item>
<item>
<title>Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-and-heor-to-advance-market-access-and-commercial-execution</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-randy-h-goodman-phd-mha-as-vice-president-of-value-strategy-and-heor-to-advance-market-access-and-commercial-execution</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide</description>
</item>
<item>
<title>Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-eric-j-daniels-md-mba-as-chief-development-officer-to-advance-clinical-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-eric-j-daniels-md-mba-as-chief-development-officer-to-advance-clinical-pipeline</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution</description>
</item>
<item>
<title>Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-granted-us-fda-orphan-drug-designation-to-reyobiqtm-in-pediatric-malignant-gliomas</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-granted-us-fda-orphan-drug-designation-to-reyobiqtm-in-pediatric-malignant-gliomas</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing</description>
</item>
<item>
<title>Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-receives-ama-pla-code-for-cnsider-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-us-commercial-adoption</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-receives-ama-pla-code-for-cnsider-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-us-commercial-adoption</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>New dedicated billing code facilitates payer reimbursement, supports clinician adoptions, and enables national utilization tracking HOUSTON, April 07, 2026</description>
</item>
<item>
<title>Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-secures-highmark-coverage-for-cnsider-csf-assay-expanding-reimbursement-to-75-million-covered-lives-7</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-secures-highmark-coverage-for-cnsider-csf-assay-expanding-reimbursement-to-75-million-covered-lives-7</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the</description>
</item>
<item>
<title>Plus Therapeutics Announces Reverse Stock Split </title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-reverse-stock-split</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (the “Company”), a clinical-stage pharmaceutical company developing targeted</description>
</item>
<item>
<title>Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-reports-granting-of-inducement-awards-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing</description>
</item>
<item>
<title>Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-diagnostics-and-molecular-diagnostics-industry-leader-ron-andrews-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-appoints-diagnostics-and-molecular-diagnostics-industry-leader-ron-andrews-to-its-board-of-directors</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and</description>
</item>
<item>
<title>Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-reports-2025-results-business-progress-and-2026-anticipated-milestones-for-reyobiqtm-clinical-program-and-cnsider-commercial-rollout-50</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-reports-2025-results-business-progress-and-2026-anticipated-milestones-for-reyobiqtm-clinical-program-and-cnsider-commercial-rollout-50</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and</description>
</item>
<item>
<title>Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-new-category-iii-cpt-code-for-convection-enhanced-delivery-used-with-reyobiqtm</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-new-category-iii-cpt-code-for-convection-enhanced-delivery-used-with-reyobiqtm</guid>
<pubDate>Wed, 25 Feb 2026 12:30:00 GMT</pubDate>
<description>Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization trackingHOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association’s (AMA) CPT® (Current Procedural Terminology) Edito</description>
</item>
<item>
<title>Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-provides-business-reyobiq-124500705</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-provides-business-reyobiq-124500705</guid>
<pubDate>Thu, 22 Jan 2026 12:45:00 GMT</pubDate>
<description>Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization. “Our 2 key goals in 2026 are CNSide commercial scale-up and REYOBIQ pivotal trial readiness,” sai</description>
</item>
<item>
<title>Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-business-host-conference-211500184</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-business-host-conference-211500184</guid>
<pubDate>Wed, 21 Jan 2026 21:15:00 GMT</pubDate>
<description>HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces that the Company will provide a business update on Thursday, January 22, 2026 before the market open. Plus Therapeutics’ management team will then host a conference call and webcast at 9:00 a.m. ET to discuss and provide additional details. Web</description>
</item>
<item>
<title>Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-pricing-upsized-130000385</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-pricing-upsized-130000385</guid>
<pubDate>Wed, 14 Jan 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces the pricing of its underwritten public offering of 39,473,684 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $0.38 per unit. The gross proceeds</description>
</item>
<item>
<title>Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-read-type-123000062</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-read-type-123000062</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pi</description>
</item>
<item>
<title>Plus Therapeutics Expands CNSide Assay Platform to State of California</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-expands-cnside-assay-123000534</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-expands-cnside-assay-123000534</guid>
<pubDate>Thu, 11 Dec 2025 12:30:00 GMT</pubDate>
<description>CNSide Diagnostics now licensed in 48 U.S. States covering over 90% of the U.S. populationHOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has been granted lab licenses to provide the CNSide® Cerebrospinal Fluid</description>
</item>
<item>
<title>Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-expansion-cnside-123000798</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-expansion-cnside-123000798</guid>
<pubDate>Tue, 09 Dec 2025 12:30:00 GMT</pubDate>
<description>HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced two new hires to its team for CNSide Diagnostics, LLC, its wholly-owned subsidiary. “We are strategically building the team to bolster our capabilities as we scale up our laboratory operations to address the largely unt</description>
</item>
<item>
<title>Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-highlights-three-reyobiq-123000818</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-highlights-three-reyobiq-123000818</guid>
<pubDate>Thu, 04 Dec 2025 12:30:00 GMT</pubDate>
<description>Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated promising safety and efficacy signal, supporting continued Phase 2 enrollment and investigation MRI combined with SPECT imaging biomarkers effectively evaluate overall survival response with REYOBIQ in recurrent GBM treatment and help guide personalized patient planning HOUSTON, Dec. 04,</description>
</item>
<item>
<title>Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-present-respect-phase-123000422</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-present-respect-phase-123000422</guid>
<pubDate>Mon, 01 Dec 2025 12:30:00 GMT</pubDate>
<description>Study findings to be featured in a poster spotlight presentationHOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025,</description>
</item>
<item>
<title>Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases</title>
<link>https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-completion-u-123000454</link>
<guid isPermaLink="true">https://6ix.com/company/plus-therapeutics-inc/news/plus-therapeutics-announces-completion-u-123000454</guid>
<pubDate>Mon, 24 Nov 2025 12:30:00 GMT</pubDate>
<description>HOUSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announced it has completed a Type B meeting with the U.S. Food and Drug Administration (FDA) on November 7th to discuss its REYOBIQ clinical development plans for leptomeningeal metastases (LM) including the design of a planned pivotal or registrational trial.</description>
</item>
</channel>
</rss>